Literature DB >> 1451136

Effects of intravenous amiodarone on electrical dispersion in normal and ischaemic tissues and on arrhythmia inducibility: monophasic action potential studies.

R D Mayuga1, D H Singer.   

Abstract

OBJECTIVE: The aim was to study the effects of intravenous amiodarone on: (1) repolarisation and other monophasic action potential characteristics of normal and ischaemic tissues, and (2) vulnerability to pacing induced repetitive ventricular firing following acute left anterior descending coronary artery ligation.
METHODS: Epicardial monophasic action potentials were continuously and simultaneously recorded from ischaemic and non-ischaemic regions of the hearts of 24 pentobarbitone anaesthetised dogs. Monophasic action potential duration, rise time, and amplitude, as well as the degree of dispersion of repolarisation between normal and ischaemic areas and vulnerability to electrical induction of repetitive ventricular firing, were determined using hand held silver-silver chloride "contact pressure" electrodes, before and 15 min after coronary ligation; and 15 min after exposure to low (10 mg.kg-1) doses of amiodarone. Similar determinations were made in drug free controls.
RESULTS: Under control conditions, monophasic action potentials from both the (potentially) ischaemic and non-ischaemic regions were comparable, dispersion of repolarisation was minimal, and repetitive ventricular firing could not be induced. Coronary ligation significantly decreased monophasic action potential duration and increased rise time in the ischaemic, but not in the non-ischaemic, regions. Dispersion of repolarisation increased markedly. Repetitive ventricular firing could be induced in all dogs. "Low dose" amiodarone caused a much greater prolongation of repolarisation duration at ischaemic than at non-ischaemic sites. Dispersion of repolarisation decreased virtually to control levels and repetitive firing could no longer be induced in six of seven dogs. "High dose" amiodarone increased ischaemic region repolarisation duration and rise time relative to the non-ischaemic region to an even greater extent than the "low" dose, with the result that dispersion of repolarisation increased rather than decreased and repetitive ventricular firing again became inducible.
CONCLUSIONS: The data indicate that: (1) intravenous amiodarone prolongs repolarisation of ischaemic tissues to a greater extent than that of normal tissues; (2) "low" dose amiodarone resulted in an overall decrease in dispersion of repolarisation, with little or no change in dispersion of rise time; (3) the "high" dose increased dispersion of both repolarisation and rise time. These changes were paralleled by changes in vulnerability to induction of repetitive ventricular firing by programmed ventricular pacing, the "low" dose being associated with decreases, and the "high" dose with further increases, in vulnerability, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451136     DOI: 10.1093/cvr/26.6.571

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  3 in total

1.  Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department.

Authors:  Y Kreiss; Y Sidi; H Gur
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

2.  Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model.

Authors:  Stefan M Sattler; Anniek F Lubberding; Lasse Skibsbye; Reza Jabbari; Reza Wakili; Thomas Jespersen; Jacob Tfelt-Hansen
Journal:  J Cardiovasc Transl Res       Date:  2019-01-07       Impact factor: 4.132

Review 3.  Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models.

Authors:  Stefan Michael Sattler; Lasse Skibsbye; Dominik Linz; Anniek Frederike Lubberding; Jacob Tfelt-Hansen; Thomas Jespersen
Journal:  Front Cardiovasc Med       Date:  2019-11-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.